TY - JOUR
T1 - Impact of Physician-Defined Flares on Quality of Life and Work Impairment
T2 - An International Survey of 2238 Patients With Psoriatic Arthritis
AU - Orbai, Ana Maria
AU - Tillett, William
AU - Grieb, Suzanne
AU - Peterson, Steve
AU - Holdsworth, Elizabeth A.
AU - Booth, Nicola
AU - Chakravarty, Soumya D.
AU - Gossec, Laure
N1 - Publisher Copyright:
© 2023 Journal of Rheumatology. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Objective. To describe psoriatic arthritis (PsA) flares and their effect on patient-reported outcomes (PROs). Methods. Cross-sectional surveys of rheumatologists/dermatologists and their patients with PsA were conducted in France, Germany, Italy, Spain, the United Kingdom, and the United States, capturing data on physician-reported patient flare status, demographics, PsA severity, and clinical outcomes. Patient-completed surveys captured data on PROs: 5-level EuroQol 5-dimension, Work Productivity and Activity Impairment questionnaire, Health Assessment Questionnaire–Disability Index, and 12-item Psoriatic Arthritis Impact of Disease questionnaire. Patients were compared by flare status using parametric and nonparametric tests. Multivariate regression was used to identify flare associations. Multivariate logistic regression adjusted for patient demographics and physician specialty assessed the effect of flare status. Results. Among 2238 patients (586 from the US, 1652 from Europe) managed by 572 physicians, physician-reported flare was present for 168 patients (7.5%), and self-reported flare was present for 95 patients (10% of available data). Mean (SD) flare count over 12 months was 2.2 (4.9), lasting on average 16.4 (16.2) days. Flare status was linked to worse PROs. Patients who had not flared in the last 12 months or had never flared had a higher quality of life, lower overall work impairment, and a lower degree of disability compared with patients who were currently experiencing a flare (all; P < 0.01). Conclusion. Actively experiencing a flare adversely affected QOL, disability, and work productivity. PsA flares should be routinely assessed and managed in clinical care.
AB - Objective. To describe psoriatic arthritis (PsA) flares and their effect on patient-reported outcomes (PROs). Methods. Cross-sectional surveys of rheumatologists/dermatologists and their patients with PsA were conducted in France, Germany, Italy, Spain, the United Kingdom, and the United States, capturing data on physician-reported patient flare status, demographics, PsA severity, and clinical outcomes. Patient-completed surveys captured data on PROs: 5-level EuroQol 5-dimension, Work Productivity and Activity Impairment questionnaire, Health Assessment Questionnaire–Disability Index, and 12-item Psoriatic Arthritis Impact of Disease questionnaire. Patients were compared by flare status using parametric and nonparametric tests. Multivariate regression was used to identify flare associations. Multivariate logistic regression adjusted for patient demographics and physician specialty assessed the effect of flare status. Results. Among 2238 patients (586 from the US, 1652 from Europe) managed by 572 physicians, physician-reported flare was present for 168 patients (7.5%), and self-reported flare was present for 95 patients (10% of available data). Mean (SD) flare count over 12 months was 2.2 (4.9), lasting on average 16.4 (16.2) days. Flare status was linked to worse PROs. Patients who had not flared in the last 12 months or had never flared had a higher quality of life, lower overall work impairment, and a lower degree of disability compared with patients who were currently experiencing a flare (all; P < 0.01). Conclusion. Actively experiencing a flare adversely affected QOL, disability, and work productivity. PsA flares should be routinely assessed and managed in clinical care.
KW - Health Assessment Questionnaire
KW - psoriatic arthritis
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85145425258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145425258&partnerID=8YFLogxK
U2 - 10.3899/jrheum.211302
DO - 10.3899/jrheum.211302
M3 - Article
C2 - 35970528
AN - SCOPUS:85145425258
SN - 0315-162X
VL - 50
SP - 76
EP - 83
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 1
ER -